STP1002 for Solid Tumors

University of Southern California, Los Angeles, CA
Solid TumorsSTP1002 - Drug
Eligibility
18+
All Sexes

Study Summary

This trialtests a new drug to find the safest dose for cancer patients.

Eligible Conditions
  • Advanced Solid Tumors

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 24 months

24 months
The pharmacokinetics of STP1002
Treatment-emergent adverse events (TEAEs)
28 days
Dose limiting toxicities (DLTs)

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

STP1002
1 of 1

Experimental Treatment

30 Total Participants · 1 Treatment Group

Primary Treatment: STP1002 · No Placebo Group · Phase 1

STP1002
Drug
Experimental Group · 1 Intervention: STP1002 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

ST Pharm Co., Ltd.Lead Sponsor
1 Previous Clinical Trials
36 Total Patients Enrolled
KCRN Research, LLCIndustry Sponsor
8 Previous Clinical Trials
417 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You can swallow pills.
You have already tried all the usual treatments that are known to help, or you cannot tolerate them.
You are expected to live for at least 3 more months.

Frequently Asked Questions

Is there still room for potential participants in this research project?

"According to clinicaltrials.gov, this medical trial is open for recruitment and was initially posted on July 30th 2020 with a most recent update occurring almost exactly one year later on September 25th 2021." - Anonymous Online Contributor

Unverified Answer

Has the FDA sanctioned STP1002 for therapeutic purposes?

"Due to the preliminary nature of this experiment, our team at Power has conservatively rated STP1002's safety with a score of 1. This is because Phase 1 trials only provide limited insight into efficacy and safety." - Anonymous Online Contributor

Unverified Answer

To what extent is the current clinical trial garnering participation?

"Affirmative. According to clinicaltrials.gov, this research endeavour was first posted on July 30th of 2020 and has been actively enrolling participants since then; the last edit took place on September 25th 2021. Altogether, it is hoped that 30 patients will be recruited from 3 distinct medical centres throughout its duration." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.